BAUSCH HEALTH COS INC (BHC) Stock Overview
NYSE:BHC - CA0717341071 - Common Stock
BHC Key Statistics, Chart & Performance
The current stock price of BHC is 7.265 USD. In the past month the price increased by 25.17%. In the past year, price increased by 16.1%.
BHC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.9 | 686.36B | ||
| JNJ | JOHNSON & JOHNSON | 17.76 | 427.67B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.54 | 255.26B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.7 | 251.87B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.28 | 247.54B | ||
| MRK | MERCK & CO. INC. | 11.04 | 212.39B | ||
| PFE | PFIZER INC | 7.31 | 140.86B | ||
| SNY | SANOFI-ADR | 10.54 | 113.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.99 | 95.77B | ||
| GSK | GSK PLC-SPON ADR | 8.91 | 80.93B | ||
| ZTS | ZOETIS INC | 24.8 | 68.37B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 53.53 | 49.03B |
Related stock screener links
About BHC
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter (OTC) products and ophthalmic surgical devices and instruments. The Salix segment consists of sales in the U.S. of gastroenterology products. The International segment consists of sales, except for sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Diversified segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Bausch + Lomb segment includes Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.
Company Info
BAUSCH HEALTH COS INC
2150 St. Elzear Blvd. West
Laval QUEBEC H7L 4A8 CA
CEO: Joseph C. Papa
Employees: 20700
Phone: 18003611448
BAUSCH HEALTH COS INC / BHC FAQ
What is the stock price of BAUSCH HEALTH COS INC today?
The current stock price of BHC is 7.265 USD. The price increased by 0.76% in the last trading session.
What is the ticker symbol for BAUSCH HEALTH COS INC stock?
The exchange symbol of BAUSCH HEALTH COS INC is BHC and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BHC stock listed?
BHC stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for BAUSCH HEALTH COS INC stock?
9 analysts have analysed BHC and the average price target is 7.35 USD. This implies a price increase of 1.16% is expected in the next year compared to the current price of 7.265. Check the BAUSCH HEALTH COS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BAUSCH HEALTH COS INC worth?
BAUSCH HEALTH COS INC (BHC) has a market capitalization of 2.69B USD. This makes BHC a Mid Cap stock.
How many employees does BAUSCH HEALTH COS INC have?
BAUSCH HEALTH COS INC (BHC) currently has 20700 employees.
What are the support and resistance levels for BAUSCH HEALTH COS INC (BHC) stock?
BAUSCH HEALTH COS INC (BHC) has a support level at 7.2 and a resistance level at 7.22. Check the full technical report for a detailed analysis of BHC support and resistance levels.
Is BAUSCH HEALTH COS INC (BHC) expected to grow?
The Revenue of BAUSCH HEALTH COS INC (BHC) is expected to grow by 5.61% in the next year. Check the estimates tab for more information on the BHC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BAUSCH HEALTH COS INC (BHC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BHC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BHC, evaluating the profitability, health, valuation and growth aspects
- BAUSCH HEALTH COS INC (BHC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BAUSCH HEALTH COS INC (BHC) Sales and EPS estimates to see what analysts future expectations are.
- BAUSCH HEALTH COS INC (BHC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BAUSCH HEALTH COS INC (BHC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BAUSCH HEALTH COS INC (BHC) Stock Chart to make your own analysis
- BAUSCH HEALTH COS INC (BHC) Latest news and press-releases to stay up to date.
Does BAUSCH HEALTH COS INC (BHC) stock pay dividends?
BHC does not pay a dividend.
When does BAUSCH HEALTH COS INC (BHC) report earnings?
BAUSCH HEALTH COS INC (BHC) will report earnings on 2025-10-28, before the market open.
What is the Price/Earnings (PE) ratio of BAUSCH HEALTH COS INC (BHC)?
The PE ratio for BAUSCH HEALTH COS INC (BHC) is 1.92. This is based on the reported non-GAAP earnings per share of 3.79 and the current share price of 7.265 USD. Check the full fundamental report for a full analysis of the valuation metrics for BHC.
What is the Short Interest ratio of BAUSCH HEALTH COS INC (BHC) stock?
The outstanding short interest for BAUSCH HEALTH COS INC (BHC) is 2.56% of its float. Check the ownership tab for more information on the BHC short interest.
BHC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BHC. When comparing the yearly performance of all stocks, BHC is one of the better performing stocks in the market, outperforming 86.92% of all stocks.
BHC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BHC. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BHC Financial Highlights
Over the last trailing twelve months BHC reported a non-GAAP Earnings per Share(EPS) of 3.79. The EPS increased by 3.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.99% | ||
| ROA | 0.36% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BHC Forecast & Estimates
9 analysts have analysed BHC and the average price target is 7.35 USD. This implies a price increase of 1.16% is expected in the next year compared to the current price of 7.265.
For the next year, analysts expect an EPS growth of 5.02% and a revenue growth 5.61% for BHC